Register Now: Advances in Spectroscopy for Pharma and Biopharmaceutical Analysis Symposium
|Articles|November 1, 2009

Spectroscopy

  • Spectroscopy-11-01-2009
  • Volume 24
  • Issue 11

A Stronger FDA: What Does It Mean for You?

Author(s)David Walsh

The FDA, like the IRS or the DMV, is one of those governmental agencies that by its very nature can inspire many with at least a hint of dread. For one thing, it can often seem that they are only heard from when something bad is happening (that is, you haven't paid your taxes, you haven't paid a speeding ticket . . . or there is an inspection of your facility on the way).

The FDA, like the IRS or the DMV, is one of those governmental agencies that by its very nature can inspire many with at least a hint of dread. For one thing, it can often seem that they are only heard from when something bad is happening (that is, you haven't paid your taxes, you haven't paid a speeding ticket . . . or there is an inspection of your facility on the way).

David Walsh

Here at Spectroscopy, we leave the politics of the "Bush FDA" versus the "Obama FDA" to others, and instead focus on what is currently happening and how it impacts the laboratories and the daily work of our readers. In other words, we try to answer the question, "What does it all mean for me?" With this in mind, columnist Bob McDowall, one of the foremost experts on not only the FDA and its policies and regulations, but compliance in general, presents his take on the recent FDA Modernization Act and the posture of the FDA and its new commissioner, Margaret Hamburg, in general. Admittedly, the title of his column gives away his point of view to a large degree, as "The Tiger Has Sharp New Teeth" tells you where he thinks the FDA is headed. Tougher enforcement, shorter compliance times, and more appear to be on deck, but as always, Bob has answers and advice on how to succeed in this new environment. For whether you believe tougher regulation and enforcement is a good thing or a bad thing, the fact is that the laboratories of many readers will be forced to confront the coming changes regardless.

At Spectroscopy, we have always made it our mission to bring readers practical, nuts-and-bolts information to help them in their daily work, and this column, aimed at those on the frontlines of materials analysis, is just one more example of this mission in action. We hope you find this column and the other columns and technical research in this issue useful, and as always, feel free to contact myself or any one of our staff members at the e-mail addresses listed.

Enjoy the issue.

David Walsh

Editor-in-Chief

David.Walsh@advanstar.com

Related to this article

Pittsburgh, Pennsylvania, USA. Beautiful Pittsburgh at twilight. | Image Credit: © checubus - stock.adobe.com
Organized by CPACT, the April 27 to 29 meeting at the Marriott Pittsburgh City Center will bring together scientists, engineers, and vendors across the process industries, with keynotes on PAT, Raman, and NIR applications and an abstract deadline of December 7, 2026.
Abstract concept of connecting molecules DNA network vector neurons | Image Credit: © bill2499 - stock.adobe.com
Garth Simpson of Purdue University outlines plans to survey more ordered molecular assemblies and to apply interface-specific chiral spectroscopy to enzyme reactors, solid-phase synthesis, spin-selective reactions, and, ultimately, a new analytical method.
Curated 2026 Evergreen Content from Spectroscopy. ©  Chanakarn -chronicles-stock.adobe.com
Spectroscopy's editors gather 143 evergreen articles from 2026, including tutorials, terminology guides, technique reviews, application surveys, peer-reviewed research and the magazine's long-running columns, and organize them by subject so readers can build lasting knowledge one topic at a time.